drugset / Trial / NCT02877160

A Study to Assess the PK of AL-794 Formulations in Healthy Subjects

NCT02877160

Phase 1 Completed 31 enrolled Alios Biopharma Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This study is a single-center, randomized, open-label crossover study to assess the pharmacokinetics and food effect of AL-794 formulations in healthy subjects.

Timeline

Start
2016-06-30
Primary completion
2017-02-28
Completion
2017-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject AL-794 Unknown 150 mg

Indications